CY1108983T1 - Μιμητικα της υπεροξειδικης δισμουτασης για την αγωγη οφθαλμικων διαταραχων και νοσων - Google Patents

Μιμητικα της υπεροξειδικης δισμουτασης για την αγωγη οφθαλμικων διαταραχων και νοσων

Info

Publication number
CY1108983T1
CY1108983T1 CY20091100442T CY091100442T CY1108983T1 CY 1108983 T1 CY1108983 T1 CY 1108983T1 CY 20091100442 T CY20091100442 T CY 20091100442T CY 091100442 T CY091100442 T CY 091100442T CY 1108983 T1 CY1108983 T1 CY 1108983T1
Authority
CY
Cyprus
Prior art keywords
treatment
diphomatise
myths
peroxide
diseases
Prior art date
Application number
CY20091100442T
Other languages
English (en)
Inventor
Robert J Collier Jr
Mark R Hellberg
Peter G Klimko
Original Assignee
Alcon, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon, Inc. filed Critical Alcon, Inc.
Publication of CY1108983T1 publication Critical patent/CY1108983T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Αποκαλύπτεται η χρήση μιμητικών της SOD, ιδιαίτερα μιμητικών της SOD συμπλόκου πεντααζακυκλικού Μn(ΙΙ), για την αγωγή του AMD, της DR και του οιδήματος του αμφιβληστροειδούς.
CY20091100442T 2001-12-14 2009-04-14 Μιμητικα της υπεροξειδικης δισμουτασης για την αγωγη οφθαλμικων διαταραχων και νοσων CY1108983T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34038901P 2001-12-14 2001-12-14
EP02786915A EP1463563B1 (en) 2001-12-14 2002-12-06 Superoxide dismutase mimics for the treatment of ocular disorders and diseases

Publications (1)

Publication Number Publication Date
CY1108983T1 true CY1108983T1 (el) 2014-07-02

Family

ID=23333158

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100442T CY1108983T1 (el) 2001-12-14 2009-04-14 Μιμητικα της υπεροξειδικης δισμουτασης για την αγωγη οφθαλμικων διαταραχων και νοσων

Country Status (19)

Country Link
US (2) US7759333B2 (el)
EP (1) EP1463563B1 (el)
JP (1) JP2005513063A (el)
KR (1) KR100951606B1 (el)
CN (2) CN1620325A (el)
AT (1) ATE422944T1 (el)
BR (1) BR0214957A (el)
CA (1) CA2470721C (el)
CY (1) CY1108983T1 (el)
DE (1) DE60231246D1 (el)
DK (1) DK1463563T3 (el)
ES (1) ES2319399T3 (el)
HK (1) HK1069785A1 (el)
MX (1) MXPA04005601A (el)
PL (1) PL210225B1 (el)
PT (1) PT1463563E (el)
SI (1) SI1463563T1 (el)
WO (1) WO2003051458A1 (el)
ZA (1) ZA200404435B (el)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1620325A (zh) * 2001-12-14 2005-05-25 艾尔科公司 治疗眼睛障碍和疾病的超氧化物歧化酶模拟物
US20050130951A1 (en) * 2003-12-11 2005-06-16 Alcon, Inc. Superoxide dismutase mimics for the treatment of optic nerve and retinal damage
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
US8598150B1 (en) 2008-04-02 2013-12-03 Jonathan R. Brestoff Composition and method for affecting obesity and related conditions
US8987245B2 (en) 2008-04-02 2015-03-24 Jonathan R. Brestoff Parker Composition and method for affecting obesity and related conditions
BRPI0918337A2 (pt) 2008-12-19 2017-05-30 Abbott Lab composto, composição farmacêutica, método de tratamento, método para tratar uma doença ou condição causada, exacerbada ou resultante de um excesso de plaquetas ou ativação indesejada de plaquetas em um paciente, método para reduzir a contagem de plaquetas circulantes em um paciente e uso
PT2433640T (pt) 2010-09-24 2020-04-03 Omnivision Gmbh Composição compreendendo sod, luteína e zeaxantina
KR101214364B1 (ko) * 2011-02-15 2012-12-21 한림대학교 산학협력단 수퍼옥사이드 디스뮤테이즈 융합 단백질을 함유하는 안과 질환 예방 또는 치료용 약제학적 조성물
CN103906756B (zh) * 2011-09-26 2020-03-03 加莱拉实验室有限责任公司 用于治疗疾病的方法
KR102531246B1 (ko) * 2021-12-23 2023-05-11 주식회사 제노포커스 수퍼옥시드 디스뮤타제 및 이의 건성 황반변성의 예방 또는 치료용 용도
WO2023224136A1 (ko) * 2022-05-16 2023-11-23 주식회사 제노포커스 수퍼옥시드 디스뮤타제 및 이의 당뇨망막병증 또는 포도막염의 예방 또는 치료용 용도

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5209926A (en) * 1990-06-12 1993-05-11 Insite Vision Incorporated Aminosteroids for ophthalmic use
US5124154A (en) * 1990-06-12 1992-06-23 Insite Vision Incorporated Aminosteroids for ophthalmic use
US6127356A (en) * 1993-10-15 2000-10-03 Duke University Oxidant scavengers
US5994339A (en) * 1993-10-15 1999-11-30 University Of Alabama At Birmingham Research Foundation Oxidant scavengers
SE9402816D0 (sv) 1994-08-24 1994-08-24 Pharmacia Ab Method and meams for drug administration
US6214817B1 (en) * 1997-06-20 2001-04-10 Monsanto Company Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity
US6180620B1 (en) * 1997-06-20 2001-01-30 G.D. Searle & Co. Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals
IL135949A0 (en) * 1997-11-03 2001-05-20 Univ Duke Substituted porphyrins
US6291506B1 (en) 1998-08-04 2001-09-18 Wisconsin Alumni Research Foundation Method of reducing retinal ganglion cell degeneration
GB9817845D0 (en) * 1998-08-17 1998-10-14 Glaxo Group Ltd Chemical compounds
WO2000023568A2 (en) 1998-10-06 2000-04-27 Albert Einstein College Of Medicine Of Yeshiva University Methods and compositions for decreasing mitochondrial overproduction of reactive oxygen species in cells
CA2374472A1 (en) 1999-05-27 2000-12-07 Monsanto Company Biomaterials modified with superoxide dismutase mimics
CN1620325A (zh) 2001-12-14 2005-05-25 艾尔科公司 治疗眼睛障碍和疾病的超氧化物歧化酶模拟物

Also Published As

Publication number Publication date
CN101092432A (zh) 2007-12-26
US20100204194A1 (en) 2010-08-12
US7759333B2 (en) 2010-07-20
DE60231246D1 (de) 2009-04-02
US8003635B2 (en) 2011-08-23
PL369607A1 (en) 2005-05-02
AU2002351267B2 (en) 2007-04-05
MXPA04005601A (es) 2004-12-06
KR20040063943A (ko) 2004-07-14
KR100951606B1 (ko) 2010-04-09
EP1463563B1 (en) 2009-02-18
EP1463563A1 (en) 2004-10-06
US20050032768A1 (en) 2005-02-10
DK1463563T3 (da) 2009-04-20
WO2003051458A1 (en) 2003-06-26
CA2470721A1 (en) 2003-06-26
ATE422944T1 (de) 2009-03-15
SI1463563T1 (sl) 2009-06-30
CN1620325A (zh) 2005-05-25
PL210225B1 (pl) 2011-12-30
CA2470721C (en) 2011-07-12
ZA200404435B (en) 2006-05-31
ES2319399T3 (es) 2009-05-07
BR0214957A (pt) 2004-12-14
AU2002351267A1 (en) 2003-06-30
JP2005513063A (ja) 2005-05-12
PT1463563E (pt) 2009-03-19
HK1069785A1 (en) 2005-06-03

Similar Documents

Publication Publication Date Title
CY1108983T1 (el) Μιμητικα της υπεροξειδικης δισμουτασης για την αγωγη οφθαλμικων διαταραχων και νοσων
BR0317026A (pt) Mìmicos de superóxido dismutase para o tratamento de distúrbios e doenças oculares
WO2002085248A3 (en) Prostanoids augment ocular drug penetration
EA200400518A1 (ru) Способы лечения глазных неоваскулярных заболеваний
DE60334134D1 (de) Ungsmethode von erhöhtem augeninnendruck und glaukom
ATE254461T1 (de) Behandlung von augenschmerzen
ATE505201T1 (de) Enzymbehandlung von nahrungsmitteln für zöliakie- sprue
EE05419B1 (et) Asendatud oksasolidinoonid kombineeritud raviks
ATE554763T1 (de) Photodynamische therapie der mit der altersbezogenen makuladegeneration verbundenen okkulten chorioidalen neovaskularisation
ZA200500719B (en) The use of the combination of ciclesonide and antihitamines for the treatment of allergic rhinitis.
CY1106155T1 (el) Χρηση παραγωγων 3-βενζολοφαινυλοξικων οξεων για την αντιμετωπιση διαταραχων του αμφιβληστροειδους
ATE375141T1 (de) Verfahren und mittel zur behandlung und vorbeugung von erkrankungen der hinteren augenkammer
TR200101149T2 (tr) Dış retina bozukluklarının tedavisi.
BR0017163A (pt) Derivados 5-hidróxi-indazol para tratamento do glaucoma
NO20044530L (no) Fremgangsmate for behandling av kognitive forstyrrelser
CY1106409T1 (el) Παραγωγα κινολινης
ATE487482T1 (de) Superoxid-dismutase-mimika zur behandlungvon augenstörungen und erkrankungen
DE60224667D1 (de) Perylenequinonen zur anwendung als sonosensitizer
DE60138385D1 (de) Heilmittel zur behandlung von erkrankungen des sehnervs
PT1178819E (pt) Glutationa-redutase para a terapia e profilaxia da sida
MXPA04010816A (es) Acidos aminoalcanfosfonicos sustituidos para el tratamiento de dolor neuropatico, trastornos afectivos y de la atencion, esquizofrenia, tinitus, miopia y otros trastornos oculares.
BRPI0417549A (pt) miméticos de superóxido dismutase para o tratamento de lesão de nervo óptico e retinal
ATE344054T1 (de) Behandlung von okularen neovaskularen erkrankungen
KR200249229Y1 (ko) 이명 치료기
DE60012163D1 (de) Verwendung von ap-1 aktivatoren zur behandlung von glaukom und erhöhtem augenblutdruck